John EvansMar 4, 20222 minAdjuvant immunotherapy alone improves DMFS in patients with stage III melanomaAmong patients with stage III melanoma with occult lymph node metastasis who choose to not undergo completion lymph node dissection...
John EvansFeb 25, 20222 minMCC recurrence rate 40%Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for...
John EvansJan 28, 20222 minDifferences in skin cancer risk factors among Asian Americans identifiedA cross-sectional survey study in the U.S. has identified differences in skin cancer risk factors among Asian American individuals. The...
John EvansJan 7, 20222 minCombination LAG-3/PD-1 inhibition superior to PD-1 inhibition monotherapy for metastatic melanomaFindings from a new study suggest that inhibiting both the LAG-3 and PD-1 immune checkpoints in patients with previously untreated...